Company intelligence / Profile preview
Paradox Immunotherapeutics
Toronto, Ontario, Canadaparadoximmuno.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Paradox Immunotherapeutics is advancing a pipeline of monoclonal antibody therapies targeting protein misfolding diseases. Their lead programs are preclinical but have shown promise in selectively binding pathogenic protein conformers without affecting normal proteins. The company has received significant industry recognition and recently secured $10 million to accelerate development toward clinical milestones.
- Therapeutic areas
- NeurologyNephrologyHematology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
SymBiosis LLC — lead investor in recent funding round; no major pharma partnerships disclosed yet but interest from large pharmaceutical companies noted due to platform potential
Beyond the preview
Go deeper on Paradox Immunotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paradox Immunotherapeutics.